News Releases

Keyword Search

Jun-10-2022
Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress
Jun-10-2022
Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress
Jun-02-2022
Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022
Jun-01-2022
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
May-26-2022
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022
May-05-2022
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results
May-02-2022
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Apr-28-2022
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results
Apr-13-2022
Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma
Apr-01-2022
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)